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in both humans and mice, in
response to endotoxin were
mapped utilizing proteomic
approaches. Multimeric
pentraxin-3 (PTX3) plasma and
aortic levels mimicked changes
observed in proteins of known








vasculature. The results reveal a
link between the systemic
inflammatory response and the
neutrophil-dependent vascular
deposition of multimeric PTX3.
Highlights
• Multimer formation of pentraxin-3 (PTX3) has been linked to outcome in sepsis.
• PTX3 plasma levels have been correlated to increases in neutrophil-derived proteins.
• Neutrophil-derived myeloperoxidase and NADPH oxidase 2 are not responsible for PTX3 oxidation.
• PTX3 multimer deposition within the aorta is neutrophil dependent.
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We have previously shown that multimers of plasma
pentraxin-3 (PTX3)werepredictiveof survival inpatientswith
sepsis. To characterize the release kinetics and cellular
source of plasma protein changes in sepsis, serial samples
were obtained from healthy volunteers (n = 10; three time
points) injected with low-dose endotoxin (lipopolysaccha-
ride [LPS]) and analyzed using data-independent acquisition
MS. The human plasma proteome response was compared
with anLPS-inducedendotoxemiamodel inmice. Proteomic
analysis of human plasma revealed a rapid neutrophil
degranulation signature, followed by a rise in acute phase
proteins. Changes in circulating PTX3 correlated with in-
creases in neutrophil-derived proteins following LPS injec-
tion. Time course analysis of the plasma proteome in mice
showed a time-dependent increase in multimeric PTX3,
alongside increases in neutrophil-derived myeloperoxidase
(MPO) upon LPS treatment. The mechanisms of oxidation-
induced multimerization of PTX3 were explored in two ge-
netic mouse models: MPO global knock-out (KO) mice and
LysMCreNox2KOmice, inwhichNADPHoxidase2 (Nox2) is
only deficient in myeloid cells. Nox2 is the enzyme respon-
sible for the oxidative burst in neutrophils. Increases in
plasma multimeric PTX3 were not significantly different be-
tween wildtype and MPO or LysM Cre Nox2 KO mice. Thus,
PTX3 may already be stored and released in a multimeric
form. Through in vivo neutrophil depletion and multiplexed
vascular proteomics, PTX3 multimer deposition within the
aorta was confirmed to be neutrophil dependent. Proteomic
analysis of aortas from LPS-injected mice returned PTX3 as
the most upregulated protein, where multimeric PTX3 was
deposited as early as 2 h post-LPS along with other
neutrophil-derived proteins. In conclusion, the rise in multi-
meric PTX3 upon LPS injection correlates with neutrophil-
related protein changes in plasma and aortas. MPO and
myeloid Nox2 are not required for the multimerization of
PTX3; instead, neutrophil extravasation is responsible for the
LPS-induced deposition of multimeric PTX3 in the aorta.
The human immune response to infection and injury has
high interindividual variation at a cellular and transcriptome
level (1). There is well-known discordance between mRNA
expression and protein levels (2). Therefore, identifying pro-
teomic features will further our understanding of the immune
response (3, 4). Information, however, on how defined in-
flammatory signals, such as endotoxin (LPS, lipopolysac-
charide), alter the human plasma proteome is currently
lacking.
Moreover, many inflammatory proteins form protein
complexes. For example, long pentraxin-3 (PTX3) is a critical
mediator of the innate immune system, capable of binding
microbial moieties acting as a pattern-recognition receptor,
leading to the opsonization of bound bacterial and
fungal components, subsequently promoting their clearance
by immune cells (5–7). PTX3 forms homomultimeric
structures through interdisulfide bond formation that de-
termines its ability to bind members of the complement
system (8, 9). While total PTX3 levels in plasma are associ-
ated with outcomes after acute coronary syndrome, closely
correlating with known markers of myocardial damage (10),
we have previously shown that multimeric forms of PTX3
were superior to the measurement of total PTX3 levels
alone in predicting mortality in patients with sepsis (11).
However, key regulators of PTX3 multimer formation remain
unknown.
In the present study, we mapped the human immune
response to low-dose endotoxemia over time, through the use
of data-independent acquisition (DIA) techniques. Further-
more, using murine models of endotoxemia and multiplexed
proteomics, we assessed the contribution of key oxidant-
generating enzymes in the regulation of PTX3 multi-
merization and reveal that vascular deposition of PTX3 in
response to sepsis is neutrophil dependent.
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EXPERIMENTAL PROCEDURES
Human Study Population
This prospective, randomized, and open-label study was approved
by the Sheffield Research Ethics Committee (UK) and the Medicines
and Healthcare Products Regulatory Agency (UK) and was conducted
in accordance with Good Clinical Practice guidelines. Subjects pro-
vided written informed consent. Inclusion criteria were age older than
18 years with no significant medical issues, no regular use of medi-
cation, and willingness to abstain from consuming caffeine (an
adenosine receptor antagonist). Exclusion criteria included any clini-
cally significant abnormality detected on screening (medical history,
physical examination, ECG, and routine blood tests), recent blood
donation or vaccination, a history of alcohol or drug abuse, or a
contraindication to study medication. The study was registered at
http://www.clinicaltrials.gov (unique identifier: NCT01846559) (12).
Human Experimental Protocol
The control arm (n = 10) of the aforementioned study was used; all
study participants were male (12). One venous cannula was inserted
into an antecubital vein in each arm. One cannula was used for blood
sampling, and the other cannula was used for administration of LPS
and intravenous fluid (250 ml 0.9% saline over 30 min prior to LPS
administration, then 500 ml 0.9% saline over 4 h after LPS adminis-
tration). About 2 ng/kg Escherichia coli O:113 LPS (Clinical Center
Reference Endotoxin, National Institutes of Health) was administered
over 1 min at t = 0 h. Venous blood samples were collected at baseline
(prior to any randomized medication), prior to LPS administration, and
at the following time points after LPS administration: 5, 15, and 30 min
and 1, 1.5, 2, 4, 6, and 24 h. Baseline, 6 h, and 24 h time points were
used for proteomics in this study. Blood samples for isolation of
plasma were collected into tubes containing trisodium citrate dihy-
drate (3.13% w/v), centrifuged immediately at 1500g for 10 min, and
the supernatant stored at −80 ◦C. Plasma aliquots used for proteomic
analysis had less than three freeze–thaw cycles. All laboratory mea-
surements were performed by staff blinded to treatment allocation.
Animal Models
All experiments were performed in accordance with UK Home
Office regulations, and the investigation conformed with the Guide for
the Care and Use of Laboratory Animals published by the US National
Institutes of Health (National Institutes of Health publication no.:
85-23, revised 1996). C57BL/6J, global myeloperoxidase (MPO)
knock-out (KO) and LysM Cre NADPH oxidase 2 (Nox2) KO mice were
injected i.p. with 9 mg/kg LPS (serotype 0.11:B4, Sigma-Aldrich).
Control animals received intraperitoneal injections with an equivalent
volume of saline. Mice were sacrificed 1, 2, 3, and 4 h after injection
(n = 3 or 4 biological replicates per time point). To achieve depletion of
neutrophils, mice were injected i.p. with 200 μg antimouse Ly-6G
antibody (n = 4) (Clone 1A8; BioLegend); control mice were injected
with 200 μg rat IgG2a isotype control antibodies (n = 5) (BioLegend).
About 20 h after antibody injection, mice were injected i.p. with 9 mg/
kg LPS and sacrificed 4 h after injection. Blood samples for isolation of
plasma were collected into tubes containing trisodium citrate dihy-
drate (3.13% w/v), an aliquot was taken for immediate RNA isolation,
and the remainder was centrifuged at 1500g for 10 min and the su-
pernatant stored at −80 ◦C. Tissue samples, 10 to 20 mg, were
washed in ice-cold PBS to remove blood contamination before ho-
mogenization in the presence of tissue lysis buffer (25 mM Tris–HCl,
110 mM NaCl, 2 mM EGTA, 5 mM EDTA, 1% Triton, and 0.1%
SDS) containing protease inhibitor cocktail (Roche) at pH 7.4. Cellular
debris was then pelleted by centrifugation, 16,000g, 15 min at 4 ◦C.
Protein concentration was measured using a BCA protein assay kit
(Thermo Fisher Scientific).
Plasma Depletion and In-solution Protein Digestion
Human plasma was depleted using High-Select top14 abundant
protein depletion columns (Thermo Fisher Scientific), whereas mouse
plasma was depleted of the top7 abundant proteins using Seppro spin
columns (Merck), following manufacturer's instructions. Protein sam-
ples were denatured by the addition of a final concentration of 6 M
urea and 2 M thiourea and reduced by the addition of a final con-
centration of 10 mM DTT followed by incubation at 37 ◦C for 1 h,
240 rpm. The samples were then cooled down to room temperature
before being alkylated by the addition of a final concentration of
50 mM iodoacetamide followed by incubation in the dark for 30 min.
Prechilled (−20 ◦C) acetone (10× volume) was used to precipitate the
samples overnight at −20 ◦C. Samples were centrifuged at 14,000g for
40 min at 4 ◦C, and the supernatant subsequently discarded. Protein
pellets were dried using a SpeedVac system (Thermo Scientific;
Savant SPD131DDA), resuspended in 0.1 M triethylamine bicarbonate
buffer, pH 8.0, containing 0.02% ProteaseMax surfactant and MS
grade trypsin/Lys-C (Promega Cooperation) (1:25 enzyme:protein),
and digested overnight at 37 ◦C, 240 rpm. An aliquot of peptide digest
was taken for tandemmass tag (TMT) labeling, while the digestion was
stopped for label-free DIA analyses by acidification with TFA. Peptides
were then purified robotically, using C18 cartridges (Bravo AssayMAP;
Agilent Technologies).
Experimental Design and Statistical Rationale
The mouse LPS time course plasma and tissue TMT analyses were
divided across two TMT-10plex sets in each experiment, containing
either three or four biological replicates per time point, and replicates
per time point were split equally across TMT groups to avoid technical
bias. A common pooled calibrator sample was also included for all
TMT experiments to enable crossgroup comparisons. The mouse
neutrophil depletion experiment contained either five or four biological
replicates per group and was analyzed using a TMT-10plex, with the
inclusion of a pooled sample. Human DIA analyses with 30 samples in
total from ten individuals at three time points were conducted as fol-
lows: samples at each time point per individual were injected for MS
analysis sequentially, with a wash gradient in between each individual,
enabling an accurate determination of protein changes induced by
LPS injection over the time course per individual. To determine
analytical reliability, variation in protein abundances across standard
HeLa digest (Pierce; Thermo Scientific) injections were determined
and compared with the variation in protein abundances across the
cohorts analyzed, on both the Q-Exactive HF and Orbitrap Fusion
Lumos Tribrid. Technical variation on both mass spectrometers was
below 15% (supplemental Fig. S1). To determine reproducibility and
validity of DIA findings, nondepleted plasma samples from the human
cohort were analyzed by label-free quantification, and significantly
changing proteins over the LPS time course were compared
(supplemental Fig. S2).
TMT Peptide Labeling
Plasma and tissue peptide samples were TMT-10plex labeled ac-
cording to the manufacturer's instructions. Samples and pool were
then grouped in equal amounts, ensuring randomization, and dried
using a SpeedVac system (Thermo Fisher Scientific; Savant
SPD131DDA). Grouped TMT samples were then reconstituted with
0.1% TFA in H2O, for peptide fractionation using high pH reversed-
phase spin columns, following the manufacturer's instructions
(Thermo Fisher Scientific).
LC–MS/MS TMT Analysis
The dried peptide samples for TMT analyses were reconstituted
with 0.05% TFA in 2% acetonitrile and separated by a nanoflow LC
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system (Dionex UltiMate 3000 RSLC nano). Samples were injected
onto a nanotrap column (Acclaim PepMap100 C18 Trap; 5 mm ×
300 μm, 5 μm, 100 Å) at a flow rate of 25 μl/min for 3 min, using 0.1%
formic acid (FA) in H2O. The following nano-LC gradient at 0.25 μl/min
was used to separate the peptides: 0 to 10 min, 4 to 10% B; 10 to
75 min, 10 to 30% B; 75 to 80 min, 30 to 40% B; 80 to 85 min, 40
to 99% B; 85 to 89.8 min, 99% B; 89.8 to 90 min, 99 to 4% B; 90 to
120 min, 4% B; where A = 0.1% FA in H2O and B = 80% acetonitrile,
0.1% FA in H2O. The nanocolumn (EASY-Spray PepMap RSLC C18;
2 μm 100 Å, 75 μm × 50 cm) set at 40 ◦C was connected to an EASY-
Spray ion source (Thermo Scientific). Spectra were collected from an
Orbitrap mass analyzer (Orbitrap Fusion Lumos Tribrid; Thermo Sci-
entific) using full MS mode (resolution of 120,000 at 400 m/z) over the
m/z range 375 to 1500. Data-dependent MS2 scan was performed
using quadrupole isolation in top speed mode using collision-induced
dissociation activation and ion trap detection in each full MS scan with
dynamic exclusion enabled. TMT reporter ion quantification was
conducted using the multinotch MS3 method (13); the top5 most
abundant MS2 fragment ions with an MS isolation window (m/z) of 0.7
were isolated, following higher-energy collisional dissociation activa-
tion and detection using the Orbitrap at a resolution of 60,000,
generating an MS3 spectrum.
DIA–MS Analysis
DIA–MS was conducted on a Q-Exactive HF (Thermo Scientific),
using the above nanoflow-LC setup. All DIA samples were spiked with
indexed retention time (iRT) peptide standards (Biognosys AG) to
enable RT alignment. A precursor MS1 scan was conducted through
the mass range of 400 to 1000m/z, and MS2 spectra were collected in
25 m/z, nonoverlapping, isolation windows, in a step-wise manner
throughout the mass range at a resolution of 30,000 (at 200 m/z). DIA
data were analyzed in Spectronaut v11 (Biognosys AG) with a spectral
library generated from data-dependent acquisition analyses of pooled
control and LPS-treated human plasma samples, searched using
Proteome Discoverer (version 2.2.0.388; Thermo Scientific) software
with the parameters described later. MS1 and MS2 intensity extraction
was set to maximum intensity, picking the highest data point within
the m/z tolerance. MS1 and MS2 mass tolerance strategies were set
to dynamic, whereby Spectronaut determines optimum tolerance
based on extensive mass calibration. The precision iRT setting was
selected within Spectronaut, utilizing a large set of calibration peptides
to improve iRT precision and accuracy. Extracted ion chromatogram
retention time extraction window was set to dynamic, dynamically
adjusting the extracted ion chromatogram window in a retention time–
dependent manner based on a large sample set during calibration.
Precursor and protein q-value cutoff was set to 0.05. A minimum of
three fragments were required for a peptide precursor to be added to
the spectral library, up to a maximum of the six most abundant frag-
ments. Quantification was conducted at an MS2 level, utilizing all
fragment ion matches within the spectral library that pass the Q-value
filter of 0.05.
MS Database Search and Analysis
Proteome Discoverer software (version 2.2.0.388) was used to
search raw data files against the human database (UniProtKB/Swiss-
Prot version 2018_02; 20,400 protein entries) using Mascot (version
2.6.0; Matrix Science). The mass tolerance was set at 10 ppm for
precursor ions and 0.8 Da for fragment ions. Trypsin was used as the
digestion enzyme with up to two missed cleavages being allowed.
Carbamidomethylation of cysteines and oxidation of methionine res-
idues were chosen as fixed and variable modifications, respectively.
Label-free quantification was conducted through the inbuilt Minora
feature detection node, alongside RT alignment using the feature
mapper node, with a maximum RT shift of 10 min being allowed.
Unique and Razor peptide precursor areas were used for quantifica-
tion, and cross-sample normalization was achieved using the total
peptide amount. The inbuilt TMT 10-plex quantification method was
assigned for detection of TMT labels. MS/MS-based peptide and
protein identifications were validated with the following filters, a
peptide probability of greater than 95.0% (as specified by the peptide
prophet algorithm), a protein probability of greater than 99.0%, and at
least two unique peptides per protein. Target false discovery rate
(FDR) for peptide spectrummatches, peptide and protein identification
was set to 1%. TMT-acquired data were again normalized using the
total peptide amount. Data were then further scaled using the control
pooled sample abundance, correcting for technical variation between
injections and TMT groups.
Immunoblotting
Laemmli sample buffer (4×) (62.5 mM Tris–HCl, pH 6.8, 10%
glycerol, 1% SDS, 0.005% bromophenol blue, and 10%
2-mercaptoethanol) or the same buffer without 2-mercaptoethanol
was mixed with protein samples and boiled at 95 ◦C for 10 min.
Protein samples were separated using 4 to 12% Bis–Tris gradient gels
(Thermo Scientific) in MOPS SDS running buffer (Thermo Scientific) at
130 V for 90 min. Gels were either stained for total protein using
SimplyBlue Safe Stain (Thermo Fisher), or proteins were transferred
onto nitrocellulose membranes in ice-cold transfer buffer (25 mM Tris
base pH 8.3; 192 mM glycine; 20% methanol) at 350 mA for 2 h.
Ponceau S red staining was used to determine efficient transfer and
equal loading before membranes were blocked in 5% fat-free milk
powder in PBS containing 0.1% Tween-20 (PBST; Sigma). Mem-
branes were incubated in primary antibodies made to appropriate
concentrations in 5% bovine serum albumin in PBST overnight at
4 ◦C. The membranes were then incubated in the appropriate light
chain–specific peroxidase-conjugated secondary antibody in 5%milk/
PBST. Antibody information is provided in supplemental Table S1.
Membranes were washed for three times in PBST for 15 min before
Western blots were developed using enhanced chemiluminescence
(GE Healthcare) on photographic films (GE Healthcare). Densitometry
analysis was done using the ImageJ analysis software.
Whole-Blood RNA Quantification
Total RNA was extracted using the miRNeasy Mini kit (Qiagen)
according to the manufacturer's recommendations. About 50 μl of
whole blood was lysed in 700 μl of QIAzol reagent. Upon vigorous
mixing and incubation, lysed cells, tissue, blood, or plasma were
combined with 140 μl of chloroform, and the solution was mixed
vigorously. Samples were then centrifuged at 12,000g for 15 min at 4
◦C. About 280 μl of upper (aqueous) phase was carefully mixed with
420 μl of 100% ethanol and then applied to columns and washed
according to the manufacturer's protocol. Total RNA was eluted in
35 μl of nuclease-free H2O by centrifugation at 9000g for 1 min at 4 ◦C.
Concentration of cellular and tissue RNA was determined by spec-
trophotometry based on absorbance at 260 nm using NanoDrop
2000c (Thermo Scientific). For gene expression levels, reverse tran-
scription was performed using the SuperScript VILO cDNA Synthesis
Kit (Invitrogen). Per sample, 2 μl of VILO RT Master Mix were com-
bined with 8 μl of sample in a 25 to 100 ng/μl dilution. Thermal cycler
stages were set as follows: incubation at 25 ◦C for 10 min and 42 ◦C
for 120 min, followed by termination of the reaction at 85 ◦C for 5 min.
RT-PCR and preamplification products were stored at −80 ◦C. Taq-
Man assays were used to assess the relative gene expression levels
(supplemental Table S2). About 2.25 μl of diluted RT product was
combined with 0.25 μl of TaqMan assay (20×) (Applied Biosystems)
and 2.5 μl of the TaqMan Universal PCR Master Mix 11 No AmpErase
UNG (2×) to a final volume of 5 μl. Reactions were loaded using a
Bravo Automated Liquid Handling Platform (Agilent). Quantitative PCR
Plasma Proteome Response to Endotoxin
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was performed on a ViiA7 RealTime PCR System (Applied Bio-
systems) at 95 ◦C for 10 min, followed by 40 cycles of 95 ◦C for 15 s
and 60 ◦C for 1 min. Relative quantification was performed using the
2-''Cq method with proprietary Viia7 software (Applied Biosystems).
Statistical Analysis
Statistical analyses were conducted using the open-source soft-
ware Perseus (14). Proteomic datasets were filtered to keep only
molecules with less than 30% missing values in one experimental
group. The remaining missing values were imputed from a normal
distribution. The relative quantities of proteins were scaled using the
inbuilt z-score function. Fold differences represented within all volcano
plots were obtained after z scoring. Multiple sample testing was
conducted by ANOVA with permutation-based FDR correction,
whereas two-sample comparisons were made using the Student's t
test again with permutation-based FDR correction with a threshold of
5%. Hierarchical clustering distance was set to Euclidean, and the
linkage method used was the average. All other data visualizations
were created in GraphPad Prism (version 8.2.0; GraphPad Software).
Schematic diagrams were created using BioRender (Biorender.com).
RESULTS
The Effect of Low-Dose Endotoxemia on the Human
Plasma Proteome
Healthy volunteers were challenged with low-dose endo-
toxin (LPS; 2 ng/kg, i.e., n = 10 individuals) (Fig. 1) (12).
Volunteer characteristics are provided in supplemental
Table S3. DIA–MS was utilized to map the protein response
FIG. 1. Overview of experiments. DIA–MS was performed in serial plasma samples from human volunteers who received low-dose endo-
toxin. TMT-based quantitation was used for plasma, and aortic samples obtained from a murine endotoxemia model. DDA, data-dependent
acquisition; DIA, data-independent acquisition; iRT, indexed retention time; LPS, lipopolysaccharide; MPO, myeloperoxidase; Nox2, NADPH
oxidase 2; TMT, tandem mass tag.
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in serial plasma samples over three time points. Initially, a
human plasma spectral library was generated through the
data-dependent acquisition analysis of pooled samples either
nondepleted, top2-depleted, or top14-depleted and high-pH
reverse phase peptide fractionated, enabling the confident
identification of 712 proteins with a minimum of two unique
peptides (Fig. 1). DIA was then conducted upon top14-
depleted plasma samples from the human LPS cohort,
enabling the identification and quantification of 608 proteins.
Hierarchical cluster analysis of significantly changing proteins
in human plasma over the 24 h LPS time course revealed two
distinct protein clusters (Fig. 2, A and B). A protein degranu-
lation response was evident, whereby proteins of neutrophil
(PTX3, S100 calcium-binding protein A9—S100A9, and
neutrophil defensin 1—DEFA1) and platelet or endothelial
origin (von Willebrand factor) were transiently increased at 6 h
post-LPS injection before returning to baseline at 24 h (cluster
1; Fig. 2B). Furthermore, a global correlation between all
proteins identified in human plasma identified S100A9 and
DEFA1 as the two strongest protein correlates to PTX3
(Pearson coefficient = 0.6 and p < 0.001, for both interactions).
A later liver-driven response was observed, where acute
phase reactants were highest in abundance at 24 h post-LPS
injection (cluster 2; Fig. 2B), including C-reactive protein
(CRP), serum amyloid A-1 (SAA1), serum amyloid A-2 (SAA2),
and lipopolysaccharide-binding protein (LBP) (Fig. 2A). Core
proteins of the degranulation and acute phase responses are
individually represented, highlighting the temporal PTX3
response over the LPS time course (Fig. 2C). Two-group
comparison volcano plots (0 h versus 6 h, 0 h versus 24 h
and 6 h versus 24 h) highlight other important plasma protein
changes over time. Protein changes only observed at 6 h after
LPS administration included the reduction in the von Wille-
brand factor–cleaving protease, a disintegrin and metal-
loproteinase with a thrombospondin type-1 motif member 13
(ADAMTS13) as well as the rise in the monocyte/macrophage
marker CD163, tyrosine protein kinase receptor UFO (AXL),
and S100A9 (supplemental Fig. S3). All significant changes
FIG. 2. The effect of low-dose endotoxemia on the human plasma proteome as revealed by data-independent acquisition MS (DIA–
MS). A, healthy human volunteers were injected with low-dose endotoxin (n = 10; LPS 2 ng/kg, i.v.). Plasma isolated at 0, 6, and 24 h after LPS
injection was analyzed by DIA–MS. Hierarchical cluster analysis of significantly changing proteins (q < 0.05) over the LPS time course is rep-
resented in a heat map. B, graphical representation of two clusters of protein changes over the LPS time course. C, core protein members of the
degranulation and acute phase responses are shown in box plots. Significance was determined by ANOVA with false discovery rate–based
correction for multiple testing. LPS, lipopolysaccharide.
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over the LPS time course in human plasma are provided in
supplemental Table S4.
Confirmation in a Murine Endotoxemia Model
We have previously shown that the redox state of PTX3 and
its oligomeric composition may serve as a marker of resolution
of inflammation in patients with sepsis (11). An increase in
PTX3 was part of the degranulation response observed in
human plasma 6 h post-LPS injection alongside neutrophil-
derived proteins such as S100A9 and DEFA1 (Fig. 2C). To
further explore the kinetics of this PTX3 response, we adopted
an LPS endotoxemic mouse model (Fig. 1). Mice were injected
with LPS (9 mg/kg, i.p.) and harvested at hourly time points (1,
2, 3, and 4 h), whereas control mice were injected with saline.
Western blot analysis of murine plasma confirmed a rapid
time-dependent increase in the abundance of multimeric PTX3
in response to LPS injection (Fig. 3A, left panel). The multimers
of PTX3 are dependent upon the formation of interdisulfide
bonds, as PTX3 multimers are undetectable under reducing
conditions (Fig. 3A, middle panel) (8). Recombinant PTX3 was
used to confirm the multimeric distribution of PTX3 by
immunoblotting (Fig. 3A, right panel). Densitometry analysis
revealed dimeric, tetrameric, and octameric forms of PTX3 to
be increased in murine plasma post LPS and undetectable in
controls (Fig. 3B). Analogous to our analysis of human plasma,
we utilized multiplexed proteomics to determine changes
within mouse plasma in response to endotoxemia. Mouse
plasma was depleted of the top7 most abundant proteins and
analyzed by TMT-based MS. C–X–C motif chemokine 2
(CXCL2), a powerful neutrophil chemoattractant (15), was
among the earliest detectable protein changes within 1 h after
LPS injection. In contrast to the low-dose endotoxemia
FIG. 3. Confirmation in a murine endotoxemia model. A, plasma isolated from mice injected with LPS (9 mg/kg, i.p.) was analyzed by
immunoblotting under both non-reducing and reducing conditions (ctrl, 1, 2, 3, and 4 h, n = 3 per time point). Recombinant PTX3 was also
separately analyzed by immunoblotting under both non-reducing and reducing conditions. B, densitometry analysis of PTX3 multimers over the
LPS time course. C, murine plasma was depleted of the top seven most abundant proteins and analyzed by TMT–based quantitative MS. A
hierarchical cluster analysis of significantly changing proteins (q < 0.01) is presented as a heat map. Significance was determined by ANOVA
with false discovery rate–based correction for multiple testing. LPS, lipopolysaccharide; PTX3, pentraxin-3; TMT, tandem mass tag.
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experiment in humans, PTX3 was not detected by MS in
mouse plasma, probably because of the differences in
depletion and MS methods (top7 versus top14 depletion and
TMT–MS versus DIA–MS [Fig. 3C]). Consistent with our find-
ings in humans, plasma levels of intercellular adhesion mole-
cule 1 (ICAM-1) were increased (Fig. 3C). The neutrophil-
derived oxidant-generating enzyme, MPO, preceded the rise
in cell–cell adhesion molecules (Fig. 3C). Gene Ontology
enrichment analyses upon proteins changing with nominal
significance (p < 0.05) over the LPS time course in humans
and mice are compared in supplemental Figure S4. Significant
plasma protein changes over the mouse LPS time course are
provided in supplemental Table S5.
MPO and Nox2 Are Not Required for PTX3 Multimer
Formation
The rise in plasma MPO after LPS injection in mice coin-
cided with the increase in multimeric forms of PTX3, where
PTX3 tetramers were also first observed 2 h post-LPS injec-
tion (Fig. 3, A–C). To determine whether MPO was the oxidant-
generating enzyme responsible for the formation of multimeric
PTX3 in response to LPS, MPO–KO mice were utilized. Mul-
timeric PTX3 was still observed in the plasma of MPO−/− mice
treated with LPS (Fig. 4A). Another prominent oxidant-
generating enzyme key to the inflammatory response is
neutrophil Nox2, responsible for the generation of reactive
oxygen species during the respiratory burst (16). However,
plasma of mice lacking Nox2 specifically in myeloid cells (17)
had similar levels of multimeric PTX3 post-LPS injection, as
wildtype mice (Fig. 4B). Thus, PTX3 multimers are not
dependent on the two key reactive oxygen species-generating
enzymes and appear to be stored and released rather than
formed during neutrophil activation.
Vascular Deposition of PTX3 and HDL-Associated
Apolipoproteins
Leukocyte extravasation is a key feature of sepsis. To
assess the time course of vascular protein changes in the
endotoxemia model, aortas were harvested from C57BL/6J
wildtype mice and analyzed by multiplexed proteomics
(baseline, 1, 2, 3, and 4 h after LPS administration). Hierar-
chical cluster analysis of significantly changing proteins
(p < 0.001) in the aorta over the 4 h LPS time course revealed
two distinct protein clusters (Fig. 5A). Notably, PTX3 was
among the most upregulated proteins within the aorta at 4 h
post LPS, mirroring increases in interferon-achievable protein
202 (IFI202), vascular cell adhesion molecule-1 (VCAM-1), and
high-density lipoprotein (HDL)–associated apolipoproteins,
including apolipoprotein-A2 (ApoA2) (cluster 2; Fig. 5A).
Reduced proteins within the aorta post-LPS injection were
primarily involved in metabolic processes, including phos-
phoenolpyruvate carboxykinase (PCK2, an enzyme that cat-
alyzes the rate-limiting step of gluconeogenesis) (cluster 1;
Fig. 5A). Significant aortic protein changes over the mouse
FIG. 4. MPO and Nox2 are not required for PTX3 multimer formation. A, plasma isolated from MPO KO mice was used to determine the
requirement of this oxidant-generating enzyme in the formation of multimeric PTX3. B, similarly, mice with Nox2 deficiency in myeloid cells
(LysM-Nox2−/−) were treated with LPS, and plasma was assessed by immunoblotting. LPS, lipopolysaccharide; MPO, myeloperoxidase; Nox2;
NADPH oxidase; PTX3, pentraxin-3.
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LPS time course are provided in supplemental Table S6.
Western blot analysis confirmed the deposition of multimeric
PTX3 within the aorta, as early as 2 h post-LPS injection
(Fig. 5, B and C). In contrast, PTX3 was undetectable in aortic
tissue from saline-injected control mice (Fig. 5B). Time-course
analysis of PTX3 within the aorta revealed high PTX3 multimer
levels at 3 h post-LPS injection (Fig. 5C). A STRING interaction
network generated upon significantly changing proteins in the
FIG. 5. Vascular deposition of PTX3 and high-density lipoprotein–associated apolipoproteins. A, aortic protein extracts isolated from
mice injected with LPS (9 mg/kg, i.p.) were quantified by TMT–based MS (ctrl, 1, 2, 3, and 4 h, n = 3 or 4 per time point). A hierarchical cluster
analysis of significantly changing proteins (p < 0.001) is shown as a heat map. Two clusters of protein changes within the aorta over the LPS time
course are graphically represented. B, the aortic PTX3 response was confirmed by immunoblotting, under both non-reducing and reducing
conditions. C, densitometry analysis of PTX3 multimers over the LPS time course. D, STRING interaction network between the significantly
changing proteins within the aorta over the LPS time course. Font size relates to significance level, whereas color represents directionality of
change. Significance was determined by ANOVA with false discovery rate–based correction for multiple testing. LPS, lipopolysaccharide; PTX3,
pentraxin-3; TMT, tandem mass tag.
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aorta highlights a relationship between PTX3 and VCAM-1 in
response to LPS (Fig. 5D). This is notable since a core feature
of both human and mouse plasma responses to LPS was the
evident increase in proteins related to cell–cell adhesion, the
most prominent of which being ICAM-1 (Figs. 2A and 3C).
Neutrophils Contribute to PTX3 Deposition Within the
Vasculature
The rapid deposition of multimeric PTX3 within the aorta, 2 h
post-LPS injection, suggests cell infiltration rather than PTX3
de novo synthesis within the vasculature, further corroborated
by the fact that PTX3 was undetectable in control aortic tissue.
Second, the PTX3 response to endotoxemia consistently
correlated closely to changes in cell adhesion molecules. To
determine to what extent neutrophils deposit PTX3 within the
vasculature, mice were treated with an anti-Ly6G antibody
(Fig. 6A). Successful depletion of neutrophils was confirmed
through whole-blood RNA analysis (Fig. 6B). Hierarchical
cluster analysis of significantly changing proteins (p < 0.05) in
the aorta after LPS injection revealed two distinct protein
clusters (Fig. 6C). LPS-treated mice depleted of neutrophils
showed reduced deposition of PTX3, S100A8, and S100A9
within the aorta compared with isotype-treated control mice
(Fig. 6D). In contrast, many extracellular matrix (ECM) proteins
were increased in abundance in aortic extracts from LPS-
treated neutrophil-depleted mice, when compared with iso-
type control mice, including nidogen-1 and 2, collagen type IV,
alpha 2, and fibrilin-1 (Fig. 6D), reflecting the high ECM-
degrading potential of infiltrating neutrophils. Significant
aortic protein changes as a result of neutrophil depletion and
LPS treatment are provided in supplemental Table S7. To rule
out that LPS-induced changes in vascular permeability rather
than leukocyte infiltration contribute to PTX3 deposition within
the aorta (18), we compared the increase in HDL-associated
apolipoproteins, such as ApoA2, apolipoprotein-C1, and
apolipoprotein-C2 (Fig. 5A). Among lipoproteins, HDL is most
likely to increase with higher vascular permeability because of
its nanoparticle size. Yet, neutrophil depletion had no influ-
ence upon apolipoprotein levels within the aorta of LPS-
treated mice (Fig. 6E).
DISCUSSION
The present study includes in-depth proteomic analyses of
the endotoxemia response in humans and mice. DIA–MS
FIG. 6. Neutrophils contribute to PTX3 deposition within the vasculature. A, wildtype mice were depleted of neutrophils by anti-Ly6G
antibody injection (i.p.) 20 h prior to LPS treatment (9 mg/kg, 4 h); control mice were treated with isotype control antibody (n = 5). B, whole-
blood RNA quantification was used to determine efficient and specific depletion of neutrophils in the circulation. C, aortic protein extracts
were analyzed by TMT–based quantitative MS. Heat map displays hierarchical clusters of significantly changing proteins (p < 0.05) between
neutrophil-depleted and isotype control mice. D, a volcano plot depicting aortic protein changes between neutrophil-depleted and isotype
control mice is shown. The MS dataset was filtered to retain proteins of known extracellular localization. E, high-density lipoprotein–associated
apolipoproteins within the aorta showed no change. Significance was determined by t test with false discovery rate–based correction for multiple
testing. LPS, lipopolysaccharide; PTX3, pentraxin-3; TMT, tandem mass tag.
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analysis from plasma derived from healthy volunteers with
low-dose endotoxemia revealed two distinct clusters of pro-
tein changes: an initial degranulation response containing
PTX3, followed by an acute phase response, including CRP,
LBP, SAA1, and SAA2. The degranulation response was further
interrogated by proteomics in a murine model of endotoxemia.
The earliest detectable change after LPS injection inmicewas a
rise in CXCL2, a potent neutrophil chemoattractant. This was
followed by a neutrophil degranulation response as evidenced
by the rise in MPO and PTX3. In vivo depletion experiments
confirmed that neutrophils are predominantly responsible for
the vascular deposition of PTX3 alongside calprotectin, a
complex of S100A8 and S100A9 that constitutes about half of
the total protein content in the neutrophil cytosol.
Studies that interrogate the human plasma proteome after a
defined inflammatory stimulus are limited (19). Furthermore, the
extent to which certain cell types and organs contribute to
temporal plasma proteome changes during the inflammatory
response is currently poorly defined (20). We therefore
analyzed the plasma proteome of healthy volunteers injected
with low-dose LPS, utilizing depletion technologies for abun-
dant plasma proteins and DIA–MS. Our DIA workflow enabled
the quantification of 608 proteins in human plasma, which
included 59 Food and Drug Administration–approved protein
biomarkers (21). A rapid degranulation response was observed
6 h post-LPS injection, followed by a later acute phase
response with primarily liver-derived plasma proteins. PTX3
followed similar kinetics to other proteins primarily known to be
secreted by neutrophils, including S100A9 and DEFA1 (22, 23).
Furthermore, CD163, a monocyte-macrophage marker, also
followed a similar profile to that of PTX3. CD163 is a known
biomarker in settings of acute inflammation and is shed by the
inflammation-responsive protease disinterring and metal-
loproteinase domain–containing protein 17 (ADAM17/TACE)
(24). CD163 negatively correlates with sepsis survival (25).
In a previous work by Calvano et al. (26), transcriptomic
profiling was conducted upon whole blood leukocytes in
humans using the same endotoxin and dose as in our study.
Rather than focusing on the transcriptional response in blood
leukocytes, our analysis of the human plasmaproteome allowed
us to quantify the contribution of other organs, such as the liver
acutephase responseasevidencedbyelevatedplasma levelsof
SAA1, SAA2, LBP, and CRP at 24 h after LPS administration.
Interestingly, the study by Calvano et al. (26) identified an in-
crease in a cluster of protein changes related to the superoxide-
generatingNADPHoxidase system, suggesting a net increase in
oxidant generation over the immune response that could
contribute to protein disulfide bond formation and protein mul-
timerization. With regard to PTX3, however, myeloid Nox2-
deficient mice had detectable PTX3 multimers. Thus, the for-
mation of the protein disulfide bonds in PTX3 is not dependent
on the NADPH oxidase–driven respiratory burst in neutrophils.
The degranulation response observed in human plasma was
confirmed in an endotoxemic mouse model, whereby the
oxidant-generating enzyme MPO correlated closely with the
detection of PTX3 multimers in plasma. MPO is a key con-
stituent of the neutrophil cytotoxic response to invading
pathogen, being released from azurophilic granules to cata-
lyze the production of the bactericidal oxidant, hypochlorous
acid (27). Critically, PTX3 is also known to be stored within
azurophilic granules of the neutrophil and therefore led us to
hypothesize that MPO could be responsible for the oxidation
and subsequent formation of PTX3 multimers in response to
LPS (28). Jaylon et al. (28) have previously reported that
monomeric PTX3 is detectable within the neutrophil and that,
upon stimulation, multimeric PTX3 is detected within cell su-
pernatants, suggesting that an active oxidation of PTX3 is
occurring upon neutrophil stimulation. However, mice defi-
cient of MPO have no change in multimeric PTX3 in response
to LPS injection when compared with wildtype animals,
demonstrating that this oxidant-generating enzyme is also not
required for PTX3 multimerization. Thus, PTX3 may already be
stored in its multimeric form.
Another common feature of both the responses to LPS in
humans and mice was the presence of cell–cell adhesion
proteins within the circulation, most prominently ICAM-1.
ICAM-1 forms a critical bridge between the endothelium and
circulating leukocytes, whereby ICAM-1 promotes the slow
rolling and subsequent infiltration of leukocytes, particularly
neutrophils, to the subendothelial space. Furthermore, soluble
ICAM-1 alongside other circulating adhesion molecules such
as the selectins that we also observe to be modulated by LPS
injection are markers of vascular inflammation (29, 30). The
rise in circulating adhesion molecules suggests an activated
endothelium as origin of adhesion molecule shedding (30).
Interestingly, recent reports have shed light on the role that
MPO plays in the promotion of neutrophil infiltration into the
vasculature (31–33).
Multiplexed vascular proteomics revealed PTX3 to be the
most significantly increased protein within the aorta, whereby
PTX3 tetramers were present as early as 2 h post-LPS injec-
tion, a rapidity that is consistent with protein deposition rather
than de novo synthesis. This deposition of PTX3 within the
aorta was again accompanied by a rise in an adhesion
molecule, VCAM-1, as well an increase in HDL-associated
apolipoproteins, including ApoA2. HDL levels rapidly decline
in patients with sepsis, and the extent of this decrease is
associated with a poor prognosis (34). Since endotoxemia
increases vascular permeability and HDL is the smallest
among all lipoproteins, LPS will facilitate leakage of HDL from
the lumen of the blood vessels (35). Finally, the in vivo
depletion of neutrophils in mice treated with LPS attenuated
PTX3 deposition within the aorta, along with a reduction in
neutrophil-derived calprotectin (S100A8 and S100A9). A
concomitant increase in many ECM proteins, including core
constituents of the endothelial basement membrane such as
nidogen-1, collagen type IV, alpha 2, and fibrilin-1, highlights
the known role of the neutrophil in matrix degradation (36).
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In conclusion, using a wide array of proteomic methodolo-
gies in both human and mouse models, we elucidated a
distinct relationship between PTX3 and neutrophils in the
context of endotoxemia and associated vascular inflamma-
tion. DIA–MS during low-dose endotoxemia in healthy volun-
teers highlighted the temporal sequence of the human plasma
proteome response, with protein degranulation being an initial
core feature, which included PTX3. Multiplexed proteomics in
mouse plasma and aortic tissue revealed the deposition of
PTX3 multimers in the vessel wall. Neither MPO nor Nox2, as
major oxidant-generating enzymes in neutrophils, is required
for PTX3 multimerization. Instead, neutrophil extravasation
accounts for the vascular deposition of PTX3 multimers during
endotoxemia.
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